Glaxo Wins FDA Approval to Sell H1N1 Vaccine

NBC reports that Glaxo has won FDA approval to sell the popular H1N1 vaccine. The British company said on Tuesday the Food and Drug Administration had approved a modified version of its FluLaval seasonal flu vaccine containing the new H1N1 strain.

The green light clears the way for it to fill a order for 7.6 million doses from the U.S. government.

We, as always, would love to hear your thoughts.

Share this article with your social network, just click below to share now!

Share |